Loading
electroCore, Inc. Stock: price and insider trades · United States
2 insiders bought €127k of shares over the last 90 days, the latest filed 22 Sept 2026.
Cluster: 2 buyers in 30 dayselectroCore, Inc.: what insiders have been doing
electroCore, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 9 insiders have disclosed 26 filings since 18 October 2025.
Both sides are active: 3 purchases worth €89k and 6 sales worth €276k, from 2 insiders and 2 insiders respectively. Taken together, the sales exceed the purchases by €187k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive and 1 chief executive. Biggest ticket of the year: €105k, sold by Lev Joshua S. and made public on 25 August 2026 (0.12% of market cap).
The last purchase on record was published on 22 September 2026, which is 25 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 26 filings here. Our records for electroCore, Inc. go back to 2021, with 47 purchases and 7 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 32.0 m USD of revenue and -14.0 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
109
Thresholds
n/a
Buy Volume
€1M
47 ops. · all time
Sell Volume
€281,458
7 ops. · all time
Who traded when
BuySaleJoshua S. Lev5 sales
Thomas J. Errico5 buys
Daniel S. Goldberger3 buys1 sale
John P. Gandolfo1 buy
Michael Fox1 buy
Since the insiders bought
- -21.1%Entry US$10.27 · Close 15 Oct 2026 US$8.10
- +61.1%Entry US$4.95 · Close at T+90 US$7.97
- +84.8%Entry US$5.00 · Close at T+365 US$9.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,267 of 24,148 companies
31.1
score / 100
Value13
Quality49
FCF yld-11%
Earn yld-19%
EV/EBITDA·
ROE·
Gross mgn87%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.28
Analyst consensus
5 analysts1.20/5
US$12.00Target US$19.17(+107%)US$26.00
Income statement
RevenueUS$32M
Gross profitUS$27.8M87% margin
EBITDA-US$11.7M-37% margin
Net income-US$14M-40.0% margin
Valuation
Beta1.05
Balance sheet & cash
Market capUS$83.7M
Total debtUS$9.4M
Free Cash Flow-US$8.3M
Profitability & ownership
ROA-55.0%
% insiders34.2%
% institutions11.6%
Last declaration on 22 September 2026
Declarations109 total
5,000 shares@ US$9.81630.047% mcap4.7% of flowCommon StockSEC:0001493152-26-043640:0
Canonical exit: 13 Dec 2026 (T+90)
5,000 shares@ US$9.80070.047% mcap100.0% of flowCommon StockSEC:0001493152-26-042472:0
55,000 shares0Common StockSEC:0001493152-26-042148:0
11,123 shares0Common StockSEC:0001493152-26-042145:0
11,123 shares0Common StockSEC:0001493152-26-042149:0
11,123 shares0Common StockSEC:0001493152-26-042150:0
15,572 shares0Common StockSEC:0001493152-26-042146:0
55,000 shares0Common StockSEC:0001493152-26-042144:0
11,123 shares0Common StockSEC:0001493152-26-042217:0
11,123 shares0Common StockSEC:0001493152-26-042151:0
12,000 shares@ US$10.220.12% mcap38.8% of flowCommon StockSEC:0001493152-26-040104:1
5,000 shares@ US$4.500.021% mcap7.1% of flowCommon StockSEC:0001493152-26-040104:2
12,000 shares@ US$4.500.051% mcap17.1% of flowCommon StockSEC:0001493152-26-040104:0
5,000 shares@ US$9.880.047% mcap15.6% of flowCommon StockSEC:0001493152-26-040104:3
3,000 shares@ US$4.500.013% mcap4.3% of flowCommon StockSEC:0001493152-26-040104:4
3,000 shares@ US$9.360.027% mcap8.9% of flowCommon StockSEC:0001493152-26-040104:5
5,000 shares@ US$9.85440.048% mcap4.7% of flowCommon StockSEC:0001493152-26-038600:0
Canonical exit: 11 Nov 2026 (T+90)
70,000 shares0Common StockSEC:0001493152-26-016542:0
16,072 shares@ US$6.020.12% mcap11.1% of flowCommon StockSEC:0001493152-26-016541:0
45,000 shares0Common StockSEC:0001493152-26-014625:0
22,803 shares@ US$4.359.6% of flowCommon StockSEC:0001493152-26-011735:0
2,889 shares0Common StockSEC:0001493152-26-004038:0
20,375 shares@ US$7.470.15% mcap17.2% of flowCommon StockSEC:0001493152-26-004039:0
2,500 shares@ US$5.054.0% of flowCommon StockSEC:0001493152-25-026370:0
1,000 shares@ US$4.840.0050% mcap0.6% of flowCommon StockSEC:0001493152-25-025873:0
Canonical exit: 2 Mar 2026 (T+90)
25 of 109 declarations
About electroCore, Inc.
electroCore, Inc. (Nasdaq: ECOR) is a United States-based commercial-stage bioelectronic medicine and wellness company focused on non-invasive neuromodulation. Headquartered in Rockaway, New Jersey, the company was founded in 2005 around the idea that vagus nerve stimulation could provide new treatment pathways for difficult-to-address conditions. Its business model combines prescription medical devices with consumer wellness offerings, giving electroCore a hybrid profile that sits between medtech and specialty consumer health.
The company’s core technology is non-invasive vagus nerve stimulation, or nVNS. Its flagship product, gammaCore, is a handheld non-invasive vagus nerve stimulator used in certain regulated medical indications, including pain-related conditions and other label-specific uses depending on market authorization. electroCore also commercializes Quell Fibromyalgia, as well as Truvaga and TAC-STIM, two products positioned for wellness, relaxation, sleep support, and human performance. This product mix allows the company to participate in prescription channels, institutional settings, and increasingly direct-to-consumer demand.
Read moreShow less
From a competitive standpoint, electroCore occupies a specialized niche in portable, non-implantable neuromodulation. The company’s differentiation lies in its non-pharmacological approach, ease of use, and a technology platform that can be deployed in both clinical and consumer settings. At the same time, it operates in a challenging market structure where larger medical device companies, established drug therapies, and reimbursement dynamics can all affect adoption. As a result, the equity story remains closely tied to commercial execution, regulatory milestones, physician uptake, and the ability to convert clinical interest into repeatable revenue.
Geographically, electroCore is primarily rooted in the United States, where it maintains its headquarters and operational base, while also building international reach through distributors and selected markets in the UK and continental Europe. Recent business updates have been constructive: in the first quarter of 2026, electroCore reported net sales of $9.6 million, up 43% year over year, and for full-year 2025 the company announced record net sales of $32.0 million. Recent disclosures also pointed to growth in the wellness segment, stronger prescription sales in the United States, and organizational changes in management. For investors, electroCore represents a small-cap healthcare innovator listed on the U.S. Nasdaq market, with a growth thesis that depends on sustained commercial scaling rather than broad product diversification.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
